Incorporando los inhibidores de CDK 4/6 a la práctica Clínica habitual

9 / 38

HR-positive
locally advanced/metastatic BC
(820/600pts)
Progressing to AI treatment
PI3k mut (wt)
Fulvestrant
+
Alpelisib/Taselisib
1
1
SOLAR 1 & SANDPIPER phase III Trials
Fulvestrant
+
Placebo